Results 181 to 190 of about 87,328 (317)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real-World Clinical Data. [PDF]

Brain Behav
Ahvenjärvi H, Lund I, Portaankorva AM, Krüger J, Ryytty M.   +4 more
europepmc   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

The effect of dance movement therapy and walking interventions on loneliness and self-neglect in older people aged 65 and over: a randomized controlled trial. [PDF]

BMC Geriatr
Das Gecim GY, Ustun G.
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study. [PDF]

BMJ Neurol Open
Rasmussen TH, Schikora-Rustad S, Lorentzen ÅR, Tran TT, Øverås MH, Myhr KM, Wergeland S, Aarseth J, Bø L, Berge T, Høgestøl EA, Harbo HF, Tveter AT, Jørgensen KK, Cunen C, Torkildsen Ø, Holmøy T, Celius EG, Vaage JT, Nygaard GO, Lund-Johansen F, König M.   +21 more
europepmc   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

DMT-Induced Shifts in Criticality Correlate with Self-Dissolution. [PDF]

J Neurosci
Irrmischer M, Aqil M, Luan L, Wang T, Engelbregt H, Carhart-Harris R, Linkenkaer-Hansen K, Timmermann C.   +7 more
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Vigilance state dissociation induced by 5-MeO-DMT in mice. [PDF]

Commun Biol
Bréant BJB, Prius Mengual J, Andrews A, Hoerder-Suabedissen A, Patel J, Bannerman DM, Sharp T, Vyazovskiy VV.   +7 more
europepmc   +1 more source